Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms

Table 2

Clinical studies of metformin for the treatment of GC.

Author	Study design	Inclusion criteria	HR
Tseng [163]	Retrospective cohort study	DM2 + antidiabetic drugs	HR: 0.45 (0.36-0.56)
Lee et al. [165]	Retrospective cohort study	GC + gastrectomy	HR: 0.58 (0.37-0.93)
de Jong et al. [168]	Retrospective cohort study	DM2 + oral antidiabetic drugs	HR: 0.97 (0.82-1.15)
Zhou et al. [183]	Meta-analysis, 7 cohort studies	GC + metformin	HR: 0.76 (0.64-0.91)
Lacroix et al. [174]	Retrospective cohort study	GC	HR: 0.86 (0.56-1.33)
Zheng et al. [169]	Prospective cohort study	DM2 + antidiabetic drugs	Noncardia: HR: 0.93 (0.78-1.12). Cardia: HR: 1.49 (1.09-2.02)
Baglia et al. [172]	Prospective cohort study	Breast, CRC, lung, and GC patients	OS-HR: 1.11 (0.81-1.53)
Seo et al. [166]	Retrospective cohort study	GC + curative gastrectomy	HR: 0.45 (0.30-0.66)
Dulskas et al. [170]	Retrospective cohort study	DM2 + GC	SIR: 0.75 (0.66-0.86)
Shuai et al. [164]	Meta-analysis, 11 cohort studies	GC + metformin	HR: 0.79 (0.62-1.00)